These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34183622)

  • 1. Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019.
    Neilson LM; Munshi KD; Peasah SK; Huang Y; Swart ECS; Henderson R; Manolis C; Good CB
    Med Care; 2021 Sep; 59(9):789-794. PubMed ID: 34183622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare.
    Barthold D; Li J; Basu A
    JAMA Netw Open; 2024 Jul; 7(7):e2420724. PubMed ID: 38980673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015.
    Khorrami P; Sinha MS; Bhanja A; Allen HL; Kesselheim AS; Sommers BD
    JAMA Netw Open; 2022 Jan; 5(1):e2140371. PubMed ID: 35029667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
    King J; McAdam-Marx C; McCaleb R; Davis D; Bemberg GB; Johnson JT
    J Manag Care Spec Pharm; 2019 Jun; 25(6):646-651. PubMed ID: 31134855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.
    Luo J; Feldman R; Rothenberger SD; Hernandez I; Gellad WF
    JAMA Netw Open; 2020 Oct; 3(10):e2020969. PubMed ID: 33057641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
    Bibeau WS; Fu H; Taylor AD; Kwan AY
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
    Chinthammit C; Axon DR; Mollon L; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
    J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445
    [No Abstract]   [Full Text] [Related]  

  • 11. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
    Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
    Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Reduced Drug Copayments on Adherence to Oral Diabetes Medications Among Childless Adults in Wisconsin Medicaid.
    Kim NH; Look KA
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1432-1441. PubMed ID: 31778619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographic Variation in Antidiabetic Agent Adherence and Glycemic Control Among Patients with Type 2 Diabetes.
    Tan E; Yang W; Pang B; Dai M; Loh FE; Hogan P
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1195-202. PubMed ID: 26679968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023.
    Hamblin PS; Earnest A; Russell AW; Talic S; Zomer E; Zoungas S
    Diabetes Obes Metab; 2024 Nov; 26(11):4924-4932. PubMed ID: 39219539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
    Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
    J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Type 2 Diabetes Medication Access and Effect of Patient Cost Sharing.
    Henk HJ; Lopez JMS; Bookhart BK
    J Manag Care Spec Pharm; 2018 Sep; 24(9):847-855. PubMed ID: 30156451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in utilization and costs of migraine medications, 2017-2020.
    Nguyen JL; Munshi K; Peasah SK; Swart ECS; Kohli M; Henderson R; Good CB
    J Headache Pain; 2022 Aug; 23(1):111. PubMed ID: 36031609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization.
    Anderson KE; Chaiyakunapruk N; Gutierrez EJ; Schmutz HW; Rose MR; Brixner D; McQueen RB
    Health Aff (Millwood); 2024 Aug; 43(8):1137-1146. PubMed ID: 39102598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.
    Lipska KJ; Ross JS; Van Houten HK; Beran D; Yudkin JS; Shah ND
    JAMA; 2014 Jun; 311(22):2331-3. PubMed ID: 24915266
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.